Aromatase inhib 
Welcome,         Profile    Billing    Logout  
 6 Companies  6 Products   6 Products   149 Diseases   442 Trials   11306 News 


12345678910111213...7576»
  • ||||||||||  letrozole / Generic mfg., exemestane / Generic mfg.
    Journal:  Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane. (Pubmed Central) -  Apr 23, 2024   
    To the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane.
  • ||||||||||  tamoxifen / Generic mfg.
    Impact of Anti-estrogen Therapy on the Vaginal Microflora in Breast Cancer Patients () -  Apr 20, 2024 - Abstract #ASBrS2024ASBrS_389;    
    While previous studies have associated anti-estrogen therapies with atrophic vaginitis, comparison of the rate of BV amongst women taking and not taking these medications is novel. Further studies should evaluate the incidence of BV and vaginal microbiome composition in women taking anti-estrogen therapies stratified by breast cancer course and surgical treatment to better understand the relationship and identify potential therapeutic avenues for improved quality of life.
  • ||||||||||  tamoxifen / Generic mfg.
    Journal, Adherence:  Follow-up Routines Matter for Adherence to Endocrine Therapy in the Adjuvant Setting of Breast Cancer. (Pubmed Central) -  Apr 17, 2024   
    Medication persistence for 4 years and more was good and similar between patients initiating aromatase inhibitor (AI) and tamoxifen (75.7% and 72.0%, respectively, P = .43)...Adherence to ET in BC is high in Western Sweden. Less regular nurse-initiated contacts between BC patients and nursesled surprisingly to a better adherence than a more regular nurse-initiated contact.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Clinical, Journal, HEOR, Real-world evidence, Real-world, Metastases:  Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study. (Pubmed Central) -  Apr 15, 2024   
    In conclusion, results highlight that DEX is able to change the activity of aromatase, and disrupt the biosynthesis of estrogens and thus affect reproduction in fish. The high-quality evidence from the BrasiLEEira study corroborates the RCTs' findings, expanding its validity to a broader spectrum and underrepresented population who may benefit from ribociclib treatment.
  • ||||||||||  duloxetine / Generic mfg.
    Review, Journal:  Current and future advances in practice: aromatase inhibitor-induced arthralgia. (Pubmed Central) -  Apr 11, 2024   
    There was consistent improvement in AIAs with switching to an alternate AI, and this could additionally allow continuation of cancer treatment with AI. Further research is needed to identify predictive biomarkers, better characterize AIA subcategories and study more reliable therapeutic options.
  • ||||||||||  Review, Journal:  Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer. (Pubmed Central) -  Apr 7, 2024   
    Unfortunately, effective strategies to target these cell survival pathways have not yet been successfully developed. Thus, there is an urgent need for the continued interrogation of autophagy and "reversible" senescence in clinically relevant breast cancer models with the long-term goal of identifying new molecular targets for improved treatment of ER+ breast cancer.
  • ||||||||||  Journal:  Nonresponse data in sexual well-being among breast reconstruction patients-who are we overlooking? (Pubmed Central) -  Apr 7, 2024   
    Sexual Well-being is the least frequently completed BREAST-Q domain, and there are demographic and clinical differences between responders and nonresponders. We encourage providers to recognize patterns in nonresponse data for Sexual-Well-being to ensure that certain patient population's sexual health concerns are not overlooked.
  • ||||||||||  Journal:  New enantioenriched ?-indolyl ketones as aromatase inhibitors: Unraveling heme-ligand interactions by MD simulation (Pubmed Central) -  Apr 5, 2024   
    An average root mean square deviation of 0.35?nm observed during a 100-ns MD simulation and binding free energy in the range of -190 to -227?kJ/mol calculated by g_mmpbsa analysis authenticated the stability of the 3c-3EQM complex. ADMET and drug-likeness parameters supported the suitability of these indole derivatives as the drug lead to develop potent inhibitors for estrogen-dependent breast cancer.
  • ||||||||||  Truqap (capivasertib) / Otsuka, AstraZeneca
    Review, Journal, Metastases:  Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer. (Pubmed Central) -  Apr 3, 2024   
    Capivasertib is a viable treatment option for patients with PIK3CA/AKT1/PTEN activating mutations following progression on endocrine-based regimens in the metastatic setting or recurrence within 12 months of completing adjuvant therapy. Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Review, Journal, Metastases:  CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety. (Pubmed Central) -  Apr 1, 2024   
    When combined with an aromatase inhibitor or fulvestrant, these agents have been approved as first-line therapy in the metastatic setting...This manuscript aims to review CDK4/6 inhibitor-related treatment-associated adverse events, identify risk factors for intolerable adverse events, and assess their safety in special patient populations such as the elderly and those with renal insufficiency. Enhanced knowledge and understanding of CDK4/6 inhibitor-related toxicities can improve treatment strategies and ultimately enhance patient care.
  • ||||||||||  Performance of FRAX (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2331;    
  • ||||||||||  Retrospective data, Review, Journal:  Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Mar 28, 2024   
    Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.
  • ||||||||||  Journal:  Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling. (Pubmed Central) -  Mar 27, 2024   
    Additionally, protein expression and phosphorylation patterns, while under different regulation, still recapitulated the estrogen-independent phenotype of ER mutant cells. Our study is the first proteome-centric characterization of ESR1 mutant models, out of which we confirm estrogen independence of ER mutants and reveal the enrichment of immune signaling pathways at the proteomic level.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Neonatal aromatase inhibition blocked defeminization of AVPV Kiss1 neurons and LH surge-generating system in male rats. (Pubmed Central) -  Mar 27, 2024   
    The results of the present study showed that the neonatal administration of letrozole (LET), a nonsteroidal aromatase inhibitor, within 2?hours of birth rescued AVPV Kiss1 expression and the LH surge in adult male rats, while the neonatal administration of testosterone propionate (TP) irreversibly attenuated AVPV Kiss1 expression and the LH surge in adult female rats...Moreover, neonatal TP administration significantly decreased the number of arcuate (ARC) Kiss1-expressing and Kiss1-Cre-activated tdTomato-positive cells and suppressed LH pulses in adult gonadectomized female rats; however, neonatal LET administration failed to affect them. These results suggest that E2 converted from neonatal testosterone is primarily responsible for the defeminization of AVPV kisspeptin neurons and the subsequent GnRH/LH surge generation in male rats.
  • ||||||||||  Retrospective data, Journal:  A computed tomography radiomics-based model for predicting osteoporosis after breast cancer treatment. (Pubmed Central) -  Mar 26, 2024   
    The predictive model combining clinical and radiomic features showed the greatest adjusted R value (0.557), sensitivity (83.6%), specificity (74.2%) and total accuracy (79.4%) compared to models that relied solely on clinical data, radiomic features, or Hounsfield units. In conclusion, the clinical-radiomic predictive model may be used as an opportunistic screening tool for early identification of breast cancer survivors at high risk of CTIBL based on non-contrast CT images of the L1 vertebra, thereby facilitating early intervention for osteoporosis.
  • ||||||||||  tranexamic acid oral / Generic mfg.
    Review, Journal:  The efficacy of medical management of leiomyoma-associated heavy menstrual bleeding: a mini review. (Pubmed Central) -  Mar 25, 2024   
    Medical management of HMB is the preferred first-line treatment and includes nonsteroidal anti-inflammatory drugs, contraceptive hormones, tranexamic acid, levonorgestrel intrauterine system, gonadotropin-releasing hormone (GnRH) antagonists and antagonists, selective progesterone receptor modulators, selective estrogen receptor modulators, and aromatase inhibitors...Patients may also face financial barriers to GnRH analog therapy. Future studies are required to delineate the nonhormonal treatment options and the long-term management of leiomyoma-associated HMB.